Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52157 | 0.80 | TAAR1 (0.53) | HPGDALDH1A1TAAR1KDM4ETDP1 | |
| SCHEMBL29706732 | 0.79 | HPGD (0.51) | HPGDPKMCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL9122187 | 0.77 | HPGD (0.39) | HPGDKDM4E | |
| SCHEMBL23501585 | 0.76 | TAAR1 (0.45) | HPGDPKMCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL31395177 | 0.76 | HPGD (0.56) | HPGDPKMCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL28466570 | 0.76 | KDM4E (0.47) | HPGDPKMCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL9449633 | 0.76 | HPGD (0.46) | HPGDPKMCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL9123178 | 0.76 | HPGD (0.39) | HPGDPKMCYP2C9CYP2C19CYP3A4 | |
| Water SCHEMBL9949680 | 0.75 | PKM (0.43) | HPGDPKMCYP2C9CYP2C19GAA | |
| Water SCHEMBL10179762 | 0.75 | PKM (0.43) | HPGDPKMCYP2C9CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103140209-B | Oral care composition with improved local flavor | 宝洁公司 | 2017-10-13 | — | — | CN | claimed |
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | claimed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | claimed |
| EP-2621462-B1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | PROCTER & GAMBLE (US) | 2020-02-12 | — | — | EP | disclosed |
| US-9937115-B2 | Oral care compositions with improved flavor | THE PROCTER & GAMBLE COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| CN-103140209-B | Oral care composition with improved local flavor | 宝洁公司 | 2017-10-13 | — | — | CN | disclosed |
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | TRPA1, TAS2R40, TAS2R30 | HPGD 3178/4885PKM 3738/4885CYP2C9 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.